

Hematology Collaboration and Licensing Deals 2016-2023

<https://marketpublishers.com/r/HF8055DCC74EN.html>

Date: October 2023

Pages: 100

Price: US\$ 3,995.00 (Single User License)

ID: HF8055DCC74EN

Abstracts

SUMMARY

Hematology Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals | Comprehensive deal directory 2016 to 2023

DESCRIPTION

Hematology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the hematology deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of hematology deals from 2016 to 2023.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals

announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of hematology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in hematology dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the hematology field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in hematology dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of hematology deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of hematology deals listed by therapeutic target.

The report also includes numerous tables and figures that illustrate the trends and activities in hematology deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Key benefits

Hematology Collaboration and Licensing Deals provides the reader with the following key benefits:

Understand deal trends since 2016

Browse hematology collaboration and licensing deals

Benchmark analysis – identify market value of transactions

Financials terms - upfront, milestone, royalties

Directory of deals by company A-Z, therapy focus and technology type

Leading deals by value

Most active dealmakers

Identify assets and deal terms for each transaction

Access contract documents - insights into deal structures

Due diligence - assess suitability of your proposed deal terms for partner companies

Save hundreds of hours of research time

Report scope

Hematology Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of hematology trends and structure of deals entered into by leading biopharma companies worldwide.

Hematology Collaboration and Licensing Deals includes:

Trends in hematology dealmaking in the biopharma industry

Overview of collaboration and licensing deal structure

Directory of hematology deal records covering pharmaceutical and biotechnology

The leading hematology deals by value

Most active hematology licensing dealmakers

In Hematology Collaboration and Licensing Deals, the available deals are listed by:

Company A-Z

Headline value

Therapeutic area

Technology type

Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.

Hematology Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

BENEFITS

Hematology Collaboration and Licensing Deals provides the reader with the following key benefits:

Understand deal trends since 2016
Browse hematology collaboration and licensing deals
Benchmark analysis – identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, therapy focus and technology type
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time

Contents

Executive Summary

CHAPTER 1 – INTRODUCTION

CHAPTER 2 – TRENDS IN HEMATOLOGY DEALMAKING

- 2.1. Introduction
- 2.2. Hematology partnering over the years
- 2.3. Hematology partnering by deal type
- 2.4. Hematology partnering by industry sector
- 2.5. Hematology partnering by stage of development
- 2.6. Hematology partnering by technology type
- 2.7. Hematology partnering by therapeutic indication

CHAPTER 3 – FINANCIAL DEAL TERMS FOR HEMATOLOGY PARTNERING

- 3.1. Introduction
- 3.2. Disclosed financials terms for hematology partnering
- 3.3. Hematology partnering headline values
- 3.4. Hematology deal upfront payments
- 3.5. Hematology deal milestone payments
- 3.6. Hematology royalty rates

CHAPTER 4 – LEADING HEMATOLOGY DEALS AND DEALMAKERS

- 4.1. Introduction
- 4.2. Most active in hematology partnering
- 4.3. List of most active dealmakers in hematology
- 4.4. Top hematology deals by value

CHAPTER 5 – HEMATOLOGY CONTRACT DOCUMENT DIRECTORY

- 5.1. Introduction
- 5.2. Hematology partnering deals where contract document available

CHAPTER 6 – HEMATOLOGY DEALMAKING BY THERAPEUTIC TARGET

6.1. Introduction

6.2. Deals by hematology therapeutic target

Deal directory

Deal directory – Hematology deals by company A-Z 2016 to 2023

Deal directory – Hematology deals by technology type 2016 to 2023

Deal type definitions

About Wildwood Ventures

Current Partnering

Current Agreements

Recent report titles from CurrentPartnering

Table of figures

Figure 1: Hematology partnering since 2016

Figure 2: Hematology partnering by deal type since 2016

Figure 3: Hematology partnering by industry sector since 2016

Figure 4: Hematology partnering by stage of development since 2016

Figure 5: Hematology partnering by technology type since 2016

Figure 6: Hematology partnering by indication since 2016

Figure 7: Hematology deals with a headline value

Figure 8: Hematology deals with upfront payment values

Figure 9: Hematology deals with milestone payment

Figure 10: Hematology deals with royalty rates

Figure 11: Active hematology dealmaking activity since 2016

Figure 12: Top hematology deals by value since 2016

I would like to order

Product name: Hematology Collaboration and Licensing Deals 2016-2023

Product link: <https://marketpublishers.com/r/HF8055DCC74EN.html>

Price: US\$ 3,995.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HF8055DCC74EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970